AR067425A1 - Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su u - Google Patents
Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su uInfo
- Publication number
- AR067425A1 AR067425A1 ARP080104064A ARP080104064A AR067425A1 AR 067425 A1 AR067425 A1 AR 067425A1 AR P080104064 A ARP080104064 A AR P080104064A AR P080104064 A ARP080104064 A AR P080104064A AR 067425 A1 AR067425 A1 AR 067425A1
- Authority
- AR
- Argentina
- Prior art keywords
- bcg
- cepa
- proteins
- calmette
- guerin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
El fragmento inmunogénico de las cepas de VRS subtipo A y VRS subtipo B, proveniente de las proteínas NS1, NS2, N, P, M, SH, M2 (ORF1), M2 (ORF2), L, F o G. El material genético que codifica para estas proteínas o fragmentos se encuentra inserto en el genoma de BCG o de manera extracromosomal en una o varias copias, cuya expresion está comandada por promotores endogenos o exogenos de BCG, constituidos o inducibles. Las proteínas o fragmentos inmunogénicos virales pueden ser expresados por BCG de forma soluble-citoplasmática, secretada extracelularmente o como proteínas unidas a membrana celular. La preparacion puede contener además combinaciones de formulaciones descritas anteriormente. La formulacion puede ser estabilizada por liofilizacion (rango de conservacion entre 4sC y 25sC) o por temperatura (-80sC) en una solucion salina tampon para ser conservada previo a su uso. Reivindicacion 1: Formulacion inmunogénica que confiere proteccion contra la infeccion o patología causada por el virus respiratorio sincicial caracterizada porque comprende cepa recombinante atenuada de Mycobacterium, preferentemente la cepa Bacilo de Calmette y Guerin (BCG), en una concentracion entre 104 - 109 bacterias, que expresa al menos una proteína o fragmento inmunogénico del virus respiratorio sincicial (VRS), en una solucion tampon salina farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2007002710A CL2007002710A1 (es) | 2007-09-20 | 2007-09-20 | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067425A1 true AR067425A1 (es) | 2009-10-14 |
Family
ID=51399051
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080104064A AR067425A1 (es) | 2007-09-20 | 2008-09-18 | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su u |
ARP190101676A AR116662A2 (es) | 2007-09-20 | 2019-06-18 | Formulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (vrs) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101676A AR116662A2 (es) | 2007-09-20 | 2019-06-18 | Formulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (vrs) |
Country Status (10)
Country | Link |
---|---|
US (1) | US8398993B2 (es) |
EP (1) | EP2207567B1 (es) |
CN (1) | CN101918029B (es) |
AR (2) | AR067425A1 (es) |
CL (1) | CL2007002710A1 (es) |
DK (1) | DK2207567T3 (es) |
ES (1) | ES2528197T3 (es) |
PE (1) | PE20090653A1 (es) |
PL (1) | PL2207567T3 (es) |
WO (1) | WO2009039178A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102021149B (zh) * | 2010-07-27 | 2013-04-24 | 张卫东 | 基因ns1缺陷型呼吸道合胞病毒及其治疗肺癌的应用 |
WO2013155205A1 (en) | 2012-04-10 | 2013-10-17 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same |
WO2014005643A1 (en) * | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
CL2013002829A1 (es) * | 2013-10-01 | 2014-04-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
MX2016016533A (es) | 2014-06-13 | 2017-05-01 | Glaxosmithkline Biologicals Sa | Combinaciones inmunogenas. |
CN104593389A (zh) * | 2015-01-27 | 2015-05-06 | 吉林大学 | 一种重组合胞病毒蛋白及其应用 |
CL2019003847A1 (es) * | 2019-12-26 | 2021-08-06 | Univ Pontificia Catolica Chile | Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv |
CL2020000857A1 (es) | 2020-03-31 | 2021-11-05 | Univ Pontificia Catolica Chile | Nuevo uso de formulación inmunogénica bcg que expresa una proteína del virus respiratorio sincicial humano contra bvrs en bovinos |
CN114748615A (zh) * | 2022-04-29 | 2022-07-15 | 成都安永鼎业生物技术有限公司 | 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0590027A4 (en) * | 1991-06-13 | 1994-10-19 | Einstein Coll Med | MUTATIONS IN MYCOBACTERIES BY INSTALLATION. |
US6566121B1 (en) * | 1991-06-13 | 2003-05-20 | Albert Einstein College Of Medicine Of Yeshiva University | Insertional mutations in mycobacteria |
US20020081317A1 (en) * | 1999-02-02 | 2002-06-27 | Mahan Michael J. | Bacteria with altered DNA adenine methylase (DAM) activity and heterologous epitope |
EP1305043A2 (en) * | 2000-07-31 | 2003-05-02 | Aventis Pasteur Limited | Respiratory syncytial virus vaccine |
US7285281B2 (en) * | 2001-06-07 | 2007-10-23 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
US7070786B2 (en) * | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
EP1830877A2 (en) * | 2004-12-01 | 2007-09-12 | Aeras Global TB Vaccine Foundation | Recombinant bcg strains with attenuated immunosuppresive properties |
-
2007
- 2007-09-20 CL CL2007002710A patent/CL2007002710A1/es unknown
-
2008
- 2008-09-17 WO PCT/US2008/076682 patent/WO2009039178A1/en active Search and Examination
- 2008-09-17 DK DK08832386.0T patent/DK2207567T3/en active
- 2008-09-17 ES ES08832386.0T patent/ES2528197T3/es active Active
- 2008-09-17 EP EP08832386.0A patent/EP2207567B1/en active Active
- 2008-09-17 US US12/679,091 patent/US8398993B2/en active Active - Reinstated
- 2008-09-17 CN CN200880114324.0A patent/CN101918029B/zh active Active
- 2008-09-17 PL PL08832386T patent/PL2207567T3/pl unknown
- 2008-09-18 AR ARP080104064A patent/AR067425A1/es not_active Application Discontinuation
- 2008-09-18 PE PE2008001628A patent/PE20090653A1/es active IP Right Grant
-
2019
- 2019-06-18 AR ARP190101676A patent/AR116662A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2207567B1 (en) | 2014-11-05 |
CN101918029B (zh) | 2015-05-20 |
CN101918029A (zh) | 2010-12-15 |
ES2528197T3 (es) | 2015-02-05 |
AR116662A2 (es) | 2021-06-02 |
PE20090653A1 (es) | 2009-06-20 |
CL2007002710A1 (es) | 2008-01-04 |
DK2207567T3 (en) | 2015-01-26 |
US8398993B2 (en) | 2013-03-19 |
EP2207567A4 (en) | 2013-05-01 |
PL2207567T3 (pl) | 2015-06-30 |
EP2207567A1 (en) | 2010-07-21 |
WO2009039178A1 (en) | 2009-03-26 |
US20110200634A1 (en) | 2011-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067425A1 (es) | Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sincicial (vrs), en una solucion salina apta para su u | |
Aggarwal et al. | Immunological priming requires regulatory T cells and IL-10–producing macrophages to accelerate resolution from severe lung inflammation | |
Zeng et al. | Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses | |
NZ591261A (en) | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin | |
WO2010149752A3 (en) | Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease | |
AR065076A1 (es) | Vacuna contra el papilomavirus | |
JP2015525572A5 (es) | ||
WO2008156778A3 (en) | Influenza m2 protein mutant viruses as live influenza attenuated vaccines | |
JP2011504366A5 (es) | ||
PE20090483A1 (es) | Vectores para la expresion multiple de genes | |
Drake et al. | Transformation of Althaea officinalis L. by Agrobacterium rhizogenes for the production of transgenic roots expressing the anti-HIV microbicide cyanovirin-N | |
WO2009063503A3 (en) | Process for purification of human tissue type plasminogen activator | |
Li et al. | HSP70 fused with GP3 and GP5 of porcine reproductive and respiratory syndrome virus enhanced the immune responses and protective efficacy against virulent PRRSV challenge in pigs | |
WO2018115509A3 (en) | New flavivirus vaccine | |
CN102311500B (zh) | 一种抗病毒融合蛋白及其应用 | |
Bąska et al. | Excretory/secretory products of Fasciola hepatica but not recombinant phosphoglycerate kinase induce death of human hepatocyte cells | |
Du et al. | Apoptin-modified human mesenchymal stem cells inhibit growth of lung carcinoma in nude mice | |
Zhang et al. | Targeting expression of antimicrobial peptide CAMA-Syn by adenovirus vector in macrophages inhibits the growth of intracellular bacteria | |
Ogura et al. | Evaluation of an edible blue-green alga, Aphanothece sacrum, for its inhibitory effect on replication of herpes simplex virus type 2 and influenza virus type A | |
WO2020163408A3 (en) | Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins | |
AR085800A1 (es) | Vacuna de rinitis equina | |
CN110563826A (zh) | 重组胚胎发育后期丰富蛋白及包含其的抗冻液 | |
Zhou et al. | Inhibition of replication of classical swine fever virus in a stable cell line by the viral capsid and Staphylococcus aureus nuclease fusion protein | |
AR120887A1 (es) | Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv | |
WO2013072917A3 (en) | Antiviral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |